PHARMACIST TECHNICIAN POCKET GUIDE

INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

RSV STOPS HERE

Not an actual patient.

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals:

- 60 years of age and older;
- 50 through 59 years of age who are at increased risk for LRTD caused by RSV.

Vaccination may not protect all recipients.[1]

Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

GSK



The Potential Impact of RSV

RSV is a common and contagious virus that usually causes mild, cold-like symptoms. But sometimes, RSV infection can progress to more severe disease involving the lower respiratory tract.[2]

Older adults, including those with certain medical conditions, are at increased risk for severe RSV infection.[2]

Not an actual patient.

Are Your Patients Aware of the Risks of RSV?
Talk to them today about vaccination against RSV with AREXVY.

Important Safety Information (cont.)

- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY

The CDC RSV Vaccine Recommendation

The CDC recommends:

Adults 60-74 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine[2]

Adults 75 years of age and older receive a single dose of RSV vaccine[2]

Please see CDC for list of CDC-identified risk factors for severe RSV disease

CDC=Centers for Disease Control and Prevention.

Not an actual patient.

Important Safety Information (cont.)

- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.



Not an actual patient.

The Potential Impact of RSV

RSV is a common and contagious virus that usually causes mild, cold-like symptoms. But sometimes, RSV infection can progress to more severe disease involving the lower respiratory tract.[2]

Older adults, including those with certain medical conditions, are at increased risk for severe RSV infection.[2]

Are Your Patients Aware of the Risks of RSV?
Talk to them today about vaccination against RSV with AREXVY.

Storage[1]

AREXVY should be refrigerated.
DO NOT FREEZE (discard if frozen).

- Store in the original package to protect vials from light.
- Store adjuvant suspension component vials and lyophilized antigen component vials between 2 °C and 8 °C (36 °F and 46 °F) before reconstitution.
- After reconstitution, administer immediately or store between 2 °C and 8 °C (36 °F and 46 °F) or at room temperature up to 25 °C (77 °F) for up to 4 hours prior to use.
- Protect from light.
- Discard reconstituted vaccine if not used within 4 hours or has been frozen.

Dosing and Administration[1]

AREXVY is supplied in 2 vials that must be reconstituted prior to administration.

Administer 1 dose (0.5 mL) of AREXVY as an intramuscular injection.

Please refer to the full Prescribing Information for AREXVY for comprehensive details.

Coadministration of AREXVY in Adults 60+ With Other Adult Vaccines

- According to the US Prescribing Information, AREXVY can be coadministered with flu vaccination. Data are not available for concomitant administration with other vaccines[1]
- According to the CDC, coadministration of RSV vaccines with other adult vaccines during the same visit is acceptable[4]
- Available data on immunogenicity of coadministration of RSV vaccines and other vaccines are currently limited[3]

Not an actual patient.

CDC=Centers for Disease Control and Prevention.

Important Safety Information (cont.)

- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

Important Safety Information (cont.)

- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY

Important Safety Information (cont.)

- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY

2

4

5

Download helpful resources at AREXVYhcp.com

Important Safety Information (cont.)

- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

References: 1. Prescribing Information for AREXVY. **2.** Respiratory syncytial virus infection (RSV). Clinical overview of RSV. Centers for Disease Control and Prevention. Accessed July 11, 2024. https://www.cdc.gov/rsv/hcp/clinical-overview/ **3.** Healthcare providers: RSV vaccination for adults 60 years of age and over. Centers for Disease Control and Prevention. Accessed July 9, 2024. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html **4.** Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2024. *MMWR*. 2024;73(32):696-702. doi:10.15585/mmwr.mm7332e1

PMUS-RSALBND250003 March 2025
Produced in USA. 0002-0036-18

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

GSK